{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T04:06:11Z","timestamp":1794542771708,"version":"4.9.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T00:00:00Z","timestamp":1554940800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12931-019-1042-x","type":"journal-article","created":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T01:20:24Z","timestamp":1554945624000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Effect of N-acetylcysteine on exacerbations of bronchiectasis (BENE): a randomized controlled trial"],"prefix":"10.1186","volume":"20","author":[{"given":"Qian","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yirepanjaing","family":"Ailiyaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruijuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingtao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuxiu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,11]]},"reference":[{"key":"1042_CR1","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1164\/rccm.201303-0411CI","volume":"188","author":"PJ McShane","year":"2013","unstructured":"McShane PJ, Naureckas ET, Tino G, Strek ME. Non-cystic fibrosis bronchiectasis. Am J RespirCrit Care Med. 2013;188:647\u201356.","journal-title":"Am J RespirCrit Care Med"},{"issue":"4","key":"1042_CR2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.arbres.2018.07.011","volume":"55","author":"Ignasi Garcia-Oliv\u00e9","year":"2019","unstructured":"Garcia-Olive I, Marin A, Rodriguez-Pons L, Abad J. Trends in admission for bronchiectasis in a third-level hospital (2008-2017). Arch Bronconeumol. 2018. \n                    https:\/\/doi.org\/10.1016\/j.arbres.2018.07.011\n                    \n                  .","journal-title":"Archivos de Bronconeumolog\u00eda"},{"key":"1042_CR3","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.ccm.2012.02.008","volume":"33","author":"GB Nair","year":"2012","unstructured":"Nair GB, Ilowite JS. Pharmacologic agents for mucus clearance in bronchiectasis. Clin Chest Med. 2012;33:363\u201370.","journal-title":"Clin Chest Med"},{"key":"1042_CR4","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/S0140-6736(18)31767-7","volume":"392","author":"PA Flume","year":"2018","unstructured":"Flume PA, Chalmers JD. Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity. Lancet. 2018;392:880\u201390.","journal-title":"Lancet."},{"issue":"Suppl 1","key":"1042_CR5","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1136\/thx.2010.136119","volume":"65","author":"MC Pasteur","year":"2010","unstructured":"Pasteur MC, Bilton D, Hill AT. British Thoracic Society bronchiectasis non-CF guideline group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010;65(Suppl 1):i1\u201358.","journal-title":"Thorax."},{"key":"1042_CR6","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1183\/13993003.01899-2015","volume":"47","author":"S Aliberti","year":"2016","unstructured":"Aliberti S, Lonni S, Dore S, McDonnell MJ, Goeminne PC, Dimakou K, et al. Clinical phenotypes in adult patients with bronchiectasis. Eur Respir J. 2016;47:1113\u201322.","journal-title":"Eur Respir J"},{"issue":"1","key":"1042_CR7","doi-asserted-by":"publisher","first-page":"1702033","DOI":"10.1183\/13993003.02033-2017","volume":"51","author":"James D. Chalmers","year":"2018","unstructured":"Chalmers JD, Polverino E. European Respiratory Society Bronchiectasis Guidelines Task Force. Macrolides, mucoactive drugs and adherence for the management of bronchiectasis. Eur Respir J. 2018;51(1).","journal-title":"European Respiratory Journal"},{"key":"1042_CR8","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1016\/j.clinthera.2007.09.003","volume":"29","author":"E Crisafulli","year":"2007","unstructured":"Crisafulli E, Coletti O, Costi S, Zanasi E, Lorenzi C, Lucic S, et al. Effectiveness of erdosteine in elderly patients with bronchiectasis and hypersecretion: a 15-day, prospective, parallel, open-label, pilot study. Clin Ther. 2007;29:2001\u20139.","journal-title":"Clin Ther"},{"key":"1042_CR9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1378\/chest.12-1763","volume":"144","author":"D Bilton","year":"2013","unstructured":"Bilton D, Daviskas E, Anderson SD, Kolbe J, King G, Stirling RG, et al. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis. Chest. 2013;144:215\u201325.","journal-title":"Chest."},{"key":"1042_CR10","doi-asserted-by":"publisher","first-page":"CD001289","DOI":"10.1002\/14651858.CD001289.pub2","volume":"5","author":"M Wilkinson","year":"2014","unstructured":"Wilkinson M, Sugumar K, Milan SJ, Hart A, Crockett A, Crossingham I. Mucolytics for bronchiectasis. Cochrane Database Syst Rev. 2014;5:CD001289. \n                    https:\/\/doi.org\/10.1002\/14651858.CD001289.pub2\n                    \n                  .","journal-title":"Cochrane Database Syst Rev"},{"key":"1042_CR11","doi-asserted-by":"publisher","unstructured":"Moitra S. N-acetylcysteine (NAC) in COPD: benefits often lost in trials. QJM. 2018. \n                    https:\/\/doi.org\/10.1093\/qjmed\/hcy166\n                    \n                  .","DOI":"10.1093\/qjmed\/hcy166"},{"key":"1042_CR12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12931-016-0500-y","volume":"18","author":"M Cazzola","year":"2017","unstructured":"Cazzola M, Calzetta L, Facciolo F, Rogliani P, Matera MG. Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation. Respir Res. 2017;18:26.","journal-title":"Respir Res"},{"key":"1042_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biopha.2018.04.011","volume":"103","author":"L Calzetta","year":"2018","unstructured":"Calzetta L, Rogliani P, Facciolo F, Rinaldi B, Cazzola M, Matera MG. N-acetylcysteine protects human bronchi by modulating the release of neurokinin a in an ex vivo model of COPD exacerbation. Biomed Pharmacother. 2018;103:1\u20138.","journal-title":"Biomed Pharmacother"},{"key":"1042_CR14","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3109\/15412555.2012.732628","volume":"10","author":"JP Zheng","year":"2013","unstructured":"Zheng JP, Wen FQ, Bai CX, Wan HY, Kang J, Chen P, et al. High-dose N-acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON study. COPD. 2013;10:164\u201371.","journal-title":"COPD."},{"key":"1042_CR15","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S2213-2600(13)70286-8","volume":"2","author":"JP Zheng","year":"2014","unstructured":"Zheng JP, Wen FQ, Bai CX, Wan HY, Kang J, Chen P, et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir Med. 2014;2:187\u201394.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"1042_CR16","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.arbres.2017.07.016","volume":"54","author":"MA Martinez-Garcia","year":"2018","unstructured":"Martinez-Garcia MA, Maiz L, Olveira C, Giron RM, de la Rosa D, Blanco M, et al. Spanish guidelines on treatment of bronchiectasis in adults. Arch Bronconeumol. 2018;54(2):88\u201398.","journal-title":"Arch Bronconeumol"},{"key":"1042_CR17","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.clnu.2012.06.002","volume":"32","author":"G Olveira","year":"2013","unstructured":"Olveira G, Olveira C, Dorado A, Garcia-Fuentes E, Rubio E, Tinahones F, et al. Cellular and plasma oxidative stress biomarkers are raised in adults with bronchiectasis. Clin Nutr. 2013;32:112\u20137.","journal-title":"Clin Nutr"},{"key":"1042_CR18","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1111\/resp.12574","volume":"20","author":"Q Qi","year":"2015","unstructured":"Qi Q, Wang W, Li T, Zhang Y, Li Y. Aetiology and clinical characteristics of patients with bronchiectasis in a Chinese Han population: a prospective study. Respirology. 2015;20:917\u201324.","journal-title":"Respirology."},{"key":"1042_CR19","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1164\/rccm.201309-1575OC","volume":"189","author":"JD Chalmers","year":"2014","unstructured":"Chalmers JD, Goeminne P, Aliberti S, McDonnell MJ, Lonni S, Davidson J, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med. 2014;189:576\u201385.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"1042_CR20","doi-asserted-by":"publisher","first-page":"1700629","DOI":"10.1183\/13993003.00629-2017","volume":"50","author":"Eva Polverino","year":"2017","unstructured":"Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50(3).","journal-title":"European Respiratory Journal"},{"issue":"6","key":"1042_CR21","doi-asserted-by":"publisher","first-page":"1700051","DOI":"10.1183\/13993003.00051-2017","volume":"49","author":"Adam T. Hill","year":"2017","unstructured":"Hill AT, Haworth CS, Aliberti S, Barker A, Blasi F, Boersma W, et al. Pulmonary exacerbation in adults with bronchiectasis: a consensus difinition for clinical research. Eur Respir J. 2017;49(6).","journal-title":"European Respiratory Journal"},{"key":"1042_CR22","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1183\/09031936.00025214","volume":"44","author":"N Gupta","year":"2014","unstructured":"Gupta N, Pinto LM, Morogan A, Bourbeau J. The COPD assessment test: a systematic review. EurRespir J. 2014;44:873\u201384.","journal-title":"EurRespir J"},{"issue":"5","key":"1042_CR23","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1080\/15412555.2018.1540034","volume":"15","author":"FC Lanza","year":"2018","unstructured":"Lanza FC, Castro RAS, de Camargo AA, Zanatta DJM, Rached S, Athanazio R, et al. COPD assessment test (CAT) is a valid and simple tool to measure the impact of bronchiectasis on affected patients. COPD. 2018;15(5):512\u20139.","journal-title":"COPD."},{"key":"1042_CR24","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2214\/ajr.165.2.7618537","volume":"165","author":"DB Reiff","year":"1995","unstructured":"Reiff DB, Wells AU, Carr DH, Cole PJ, Hansell DM. CT findings in bronchiectasis: limited value in distinguishing between idiopathic and specific types. AJR Am J Roentgenol. 1995;165:261\u20137.","journal-title":"AJR Am J Roentgenol"},{"key":"1042_CR25","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1471-2466-13-35","volume":"13","author":"S Kim","year":"2013","unstructured":"Kim S, Oh J, Kim YI, Ban HJ, Kwon YS, Oh IJ, et al. Differences in classification of COPD group using COPD assessment test (CAT) or modified Medical Research Council (mMRC) dyspnea scores: a cross-sectional analysis. BMC Pulm Med. 2013;13:35.","journal-title":"BMC Pulm Med."},{"key":"1042_CR26","first-page":"222","volume":"12","author":"Y Ma","year":"2015","unstructured":"Ma Y, Niu Y, Tian G, Wei J, Gao Z. Pulmonary function abnormalities in adult patients with acute exacerbation of bronchiectasis: a retrospective risk factor analysis. ChronRespir Dis. 2015;12:222\u20139.","journal-title":"ChronRespir Dis"},{"key":"1042_CR27","doi-asserted-by":"publisher","first-page":"e71109","DOI":"10.1371\/journal.pone.0071109","volume":"8","author":"FC Ringshausen","year":"2013","unstructured":"Ringshausen FC, de Roux A, Pletz MW, Hamalainen N, Welte T, Rademacher J. Bronchiectasis-associated hospitalizations in Germany, 2005-2011: a population-based study of disease burden and trends. PLoS One. 2013;8:e71109.","journal-title":"PLoS One"},{"key":"1042_CR28","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/S0140-6736(12)60953-2","volume":"380","author":"C Wong","year":"2012","unstructured":"Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380:660\u20137.","journal-title":"Lancet."},{"key":"1042_CR29","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1001\/jama.2013.2290","volume":"309","author":"DJ Serisier","year":"2013","unstructured":"Serisier DJ, Martin ML, McGuckin MA, Lourie R, Chen AC, Brain B, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA. 2013;309:1260\u20137.","journal-title":"JAMA."},{"key":"1042_CR30","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1001\/jama.2013.1937","volume":"309","author":"J Altenburg","year":"2013","unstructured":"Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EH, Koppers RJ, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA. 2013;309:1251\u20139.","journal-title":"JAMA."},{"key":"1042_CR31","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1016\/j.rmed.2011.07.019","volume":"105","author":"F Kellett","year":"2011","unstructured":"Kellett F, Robert NM. Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis. Respir Med. 2011;105:1831\u20135.","journal-title":"Respir Med"},{"key":"1042_CR32","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1136\/thoraxjnl-2014-205587","volume":"69","author":"D Bilton","year":"2014","unstructured":"Bilton D, Tino G, Barker AF, Chambers DC, De Soyza A, Dupont LJ, et al. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial. Thorax. 2014;69:1073\u20139.","journal-title":"Thorax."},{"key":"1042_CR33","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1378\/chest.12-2357","volume":"144","author":"HN Tse","year":"2013","unstructured":"Tse HN, Raiteri L, Wong KY, Yee KS, Ng LY, Wai KY, et al. High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study. Chest. 2013;144:106\u201318.","journal-title":"Chest."},{"key":"1042_CR34","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.rmed.2016.06.015","volume":"117","author":"F Blasi","year":"2016","unstructured":"Blasi F, Page C, Rossolini GM, Pallecchi L, Matera MG, Rogliani P, et al. The effect of N-acetylcysteine on biofilms: implications for the treatment of respiratory tract infections. Respir Med. 2016;117:190\u20137.","journal-title":"Respir Med"},{"key":"1042_CR35","doi-asserted-by":"publisher","first-page":"e189","DOI":"10.1111\/j.1365-4632.2012.05767.x","volume":"53","author":"FI Jabr","year":"2014","unstructured":"Jabr FI. Skin rash after oral N-acetylcysteine for kidney protection. Int J Dermatol. 2014;53:e189\u201390.","journal-title":"Int J Dermatol"},{"key":"1042_CR36","first-page":"57","volume":"21","author":"T Yamamoto","year":"2014","unstructured":"Yamamoto T, Spencer T, Dargan PI, Wood DM. Incidence and management of N-acetylcysteine-related anaphylactoid reactions during the management of acute paracetamol overdose. Eur J Emerg Med. 2014;21:57\u201360.","journal-title":"Eur J Emerg Med"},{"key":"1042_CR37","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12890-018-0638-0","volume":"18","author":"R Chandrasekaran","year":"2018","unstructured":"Chandrasekaran R, Mac Aogain M, Chalmers JD, Elborn SJ, Chotirmall SH. Geographic variation in the aetiology, epidemiology and microbiology of bronchiectasis. BMC Pulm Med. 2018;18:83.","journal-title":"BMC Pulm Med"},{"key":"1042_CR38","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/resp.12528","volume":"20","author":"WJ Guan","year":"2015","unstructured":"Guan WJ, Gao YH, Xu G, Lin ZY, Tang Y, Li HM, et al. Aetiology of bronchiectasis in Guangzhou, southern China. Respirology. 2015;20:739\u201348.","journal-title":"Respirology."},{"key":"1042_CR39","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.arbres.2016.12.003","volume":"53","author":"C Olveira","year":"2017","unstructured":"Olveira C, Padilla A, Martinez-Garcia MA, de la Rosa D, Giron RM, Vendrell M, et al. Etiology of bronchiectasis in a cohort of 2047 patients. An analysis of the Spanish historical bronchiectasis registry. Arch Bronconeumol. 2017;53:366\u201374.","journal-title":"Arch Bronconeumol"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-019-1042-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12931-019-1042-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-019-1042-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T19:30:16Z","timestamp":1586460616000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-019-1042-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,11]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1042"],"URL":"https:\/\/doi.org\/10.1186\/s12931-019-1042-x","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,11]]},"assertion":[{"value":"2 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Ethics Committee of Qilu Hospital of Shandong University (clinical trial registration No. NCT02088216). All patients gave written informed consent for participation in this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients\u2019 data were collected with consent from individual patient at the time of enrollment throughout data collection period.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"73"}}